Stroke data tie Cerebrolysin to better cognition after prior decline

The main finding is that Cerebrolysin was tied to better thinking scores 90 days after a moderate stroke, and the gain was larger in people whose thinking had already declined before the stroke ¹. The study behind this was C-REGS2, a prospective multinational comparative-effectiveness study that enrolled 1,769 patients with a moderate acute ischemic stroke, defined by a stroke severity score of 8 to 15 ¹. Of those, 1,021 received Cerebrolysin as an add-on to standard care, and 748 received standard care alone ¹.

The researchers split patients by whether they had pre-stroke cognitive impairment, using a questionnaire completed by a family member or close contact ¹. At day 90, the Cerebrolysin group scored 3.24 points higher on the Montreal Cognitive Assessment, a 30-point test of memory, attention, language, and orientation, among people with prior cognitive decline ¹. In people without prior decline, the difference was 0.8 points ¹. No group differences in safety or adverse events were observed ¹. In the subgroup who received clot-dissolving treatment, the effect was again larger in people with prior cognitive decline, at 3.25 points, while the smaller effect in people without prior decline was less certain ¹.

The second report is from a rat model of closed traumatic brain injury, not from people. It suggests that two proteins in brain tissue may help track how the brain responds to injury and treatment ². The study used 101 rats with a closed brain injury. Researchers measured two proteins in brain tissue: aquaporin-4, a protein that helps water move across brain cell membranes, and olfactomedin-4, a protein linked to inflammation and repair ². Aquaporin-4 tracked the early response of astrocytes, the brain's support cells, and changed with pharmacological treatment ². Olfactomedin-4 showed a two-phase pattern: it dropped in the early phase, then rose gradually, and the speed of that rise depended on whether the animals received a treatment called citicoflavin or Cerebrolysin ². This study does not show that Cerebrolysin improved behavior in the rats. It points to possible biological markers for future research.

The third report is a single case description, not a controlled trial. It describes a child with a rare set of facial features and atypical autism whose two core autism features were no longer present after a long individualized treatment that included Cerebrolysin given as an injection into a muscle ³. The report describes a six-year-old boy with delayed development across several areas and atypical autism, a form of autism with unusual features ³. He had severe impairment of social interaction, poor name response, reduced eye contact, hand flapping, speech delay, and marked deficits in daily functioning ³. He also had multiple craniofacial features, including low-set ears, wide-set eyes, a broad nasal bridge, and a thin upper lip, suggesting an unrecognized syndromic disorder ³. After prolonged individualized treatment with Cerebrolysin injected into a muscle as the main component, the authors report complete remission of the two principal diagnostic features: poor social interaction and communication ³. The authors state this is the 21st published case in which these core features resolved with this approach ³. As a case report, it has no comparison group, so the role of Cerebrolysin cannot be separated from natural development or other parts of the individualized care.

The three reports do not share the same outcome, so they cannot be pooled. One is a large human stroke analysis, one is a rat marker study, and one is a single case report. Each adds a small piece to a larger picture.

The stroke cognition finding fits a body of research in which Cerebrolysin has been tested most often in acute stroke, with modest advantages on recovery measures, but no clear survival benefit. A 2025 meta-analysis of 14 randomized stroke trials found a 1.39-point greater improvement on the standard stroke severity scale, without excess mortality ⁴. A Cochrane review of acute ischemic stroke found no effect on death ⁵. In a randomized trial of post-stroke aphasia, Cerebrolysin plus speech therapy produced 14.8 additional points on a language battery at day 90 ⁶. For traumatic brain injury, a prospective cohort reported better consciousness scores at discharge and higher six-month survival, 59.4 percent versus 27.8 percent ⁷. In a small ALS trial, the Cerebrolysin group improved by 2.3 points on a functional scale while the placebo group declined by 0.9 points ⁸. In Alzheimer's disease, a dose-finding randomized trial reported global clinical improvement at week 24 ⁹.

The C-REGS2 main results already reported better day-90 disability and cognition scores ¹⁰. The new abstract adds a cognitive focus and shows the benefit concentrated in patients with pre-stroke cognitive impairment ¹. That is the piece that extends the older evidence.

The stroke cognition analysis is an abstract, not a full peer-reviewed paper, so details may change ¹. The rat marker study shows protein changes but does not show functional recovery in the animals ². The autism case report is one child with a rare syndrome and no comparator, so the outcome cannot be attributed to Cerebrolysin alone ³. The long-term durability of cognitive gains beyond 90 days is not known from this analysis ¹. No new safety concerns appeared, but the existing Cochrane review flagged a possible increase in nonfatal serious adverse events on the 30 mL for 10 days stroke schedule ⁵. That remains part of the picture.

In the research so far, the strongest new finding is that Cerebrolysin may help thinking after stroke most in people who already had cognitive decline, while the other two reports are early and leave many questions open.